Drug intelligence / Profile preview

CGP35348

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Intraperitoneal, Intracerebroventricular

Overview

CGP35348 is a synthetic small molecule used primarily as a research tool; it functions as a selective antagonist at the gamma-aminobutyric acid type B (GABAB) receptor. By inhibiting GABAB receptor activity, CGP35348 has been shown to block baclofen-induced antinociception, reverse gamma-hydroxybutyrate (GHB) effects on locomotor activity and dopamine release, and influence learning, memory, and neuromotor functions in animal models. It is primarily used in neuropharmacological research to investigate the physiological and behavioral roles of GABAB receptor signaling[1][3][4][6][7][8][9][10].

Other names: (S)-(3-aminopropyl)(diethoxymethyl)phosphinic acid

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on CGP35348.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGP35348.

Explore the full profile